Adult Stem Cell Company Bags Coveted 'Company of the Year' Award
Theravitae, the international biotechnology company headquartered in Thailand, was recently hailed as 'Biotechnology Company of the Year' by international global growth consulting company Frost & Sullivan. TheraVitae is the producer of VesCell, an innovative adult stem cell therapy for heart disease and peripheral arterial disease (PAD). The ceremony to reward Asia-Pacific excellence in healthcare, in various categories, was held at the Shangri-La hotel in Singapore. Bangkok, Thailand (PRWEB) July 10, 2007 -- Theravitae recently received prestigious recognition at the annual 'Excellence in Healthcare Awards' ceremony sponsored by global growth consulting company Frost & Sullivan. The awards spanned many categories but focused on recognizing best practices in the Asia -Pacific healthcare industry. This year's award ceremony was the first held in Southeast Asia that covered major areas of the healthcare industry. In granting TheraVitae the 'Biotechnology Company of the Year' award, Frost & Sullivan's team of experts has honored the company for its advancements in research, development and commercialization of an adult stem cell therapy that to date has helped hundreds of patients. The award acknowledges TheraVitae's pioneering stem cell technology platform with current therapies for the treatment of severe heart disease and PAD. The President of Theravitae, Mr. Narin "Jimmy" Apichairuk, who was present to receive the award, expressed his gratitude to Frost & Sullivan and his delight at the recognition bestowed upon the company. He accepted the award with these words: "We are honored to be a recipient of this prestigious award and we carry the responsibility to further help the progress of discoveries within the regenerative medicine field. Our industry is on the verge of redefining conventional healthcare through the miracles of adult stem cells and their remarkable ability to facilitate the regeneration of personal health. Despite the constant questionable claims of those in the embryonic lobby, it is adult stem cells which will be the first to successfully treat diabetes, Parkinson's and Alzheimers - embryonic stem cell therapies lag not by months, but by years, if not decades! " He proudly continued with TheraVitae's promise to heart patients of the world: "If you are an end-stage no-option heart patient, no cardiologist in the world can help you as much as TheraVitae can - unless that cardiologist is using adult stem cells." Theravitae has a mission to make the benefits of adult stem cell therapy accessible and affordable to the millions of people suffering from diseases once seen as incurable. The company is expanding rapidly and construction is underway for the largest semi-automated stem cell laboratory in the region. About TheraVitae: TheraVitae is a private, multinational company focused on using stem cells from the patient's own blood in order to treat a variety of disorders, especially cardiovascular diseases. The company has developed a proprietary stem cell technology, 'VesCell', that is currently being used by hospitals in Thailand and Singapore to treat patients with heart disease and peripheral artery disease. VesCell -- A Natural Treatment for Heart Disease and Peripheral Arterial Disease (PAD) The body has natural ways of healing itself and the cardiovascular system is no exception. Angiogenic Cell Precursors (ACPs) originate in bone marrow and then circulate in the blood vessels. To manufacture VesCell, TheraVitae expands a small number of ACPs harvested from about 250cc of blood into a therapeutic quantity. VesCell is injected either through a coronary artery via catheter, or during surgery, directly into the heart muscle. A key aspect of VesCell therapy is the advanced cell isolation and expansion technique that allows for the ACPs to be harvested from blood collected in a procedure similar to a common blood donation. VesCell uses a patient's own adult stem cells to treat Heart Disease and PAD and is a viable therapeutic possibility for heart or PAD patients without any other treatment option. TheraVitae Corporate Web Site: http://www.theravitae.com
VesCell Web Site: http://www.vescell.com ###
Simillar Articles
| 
